Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07TWK
|
|||
| Former ID |
DNCL003468
|
|||
| Drug Name |
TCN-P
|
|||
| Synonyms |
TRICIRIBINE PHOSPHATE; 61966-08-3; TCN-P; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Company |
Cahaba Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H17N6O7P
|
|||
| Canonical SMILES |
CN1C2=NC=NC3=C2C(=CN3C4C(C(C(O4)COP(=O)(O)O)O)O)C(=N1)N
|
|||
| InChI |
1S/C13H17N6O7P/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(21)8(20)6(26-13)3-25-27(22,23)24/h2,4,6,8-9,13,20-21H,3H2,1H3,(H2,14,17)(H2,22,23,24)/t6-,8-,9-,13-/m1/s1
|
|||
| InChIKey |
URLYINUFLXOMHP-HTVVRFAVSA-N
|
|||
| CAS Number |
CAS 61966-08-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00363454) Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.